insights_auto
Why is 1MK down 2.70%?
Dive Deeperchevron_right
1MK:FRA
Mauna Kea Technologies SA
€0.10
arrow_downward
-2.70%(-0.0028) 1D
Oct 13, 8:03:08 AM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 1MK...
Open
€0.10
High
€0.10
Low
€0.10
Mkt. cap
20.40M
Avg. vol.
4.78K
Volume
0.00
P/E ratio
0.83
52-wk high
€0.21
52-wk low
€0.05
EPS
€0.12
No. of employees
59
Open
€0.10
High
€0.10
Low
€0.10
Mkt. cap
20.40M
Avg. vol.
4.78K
Volume
0.00
P/E ratio
0.83
52-wk high
€0.21
52-wk low
€0.05
EPS
€0.12
No. of employees
59
News stories
From web sources and news partners
Morningstar
·
49 minutes ago
XCF Global (Nasdaq:SAFX) Announces $12M+ in Gross Product Sales and Shipments of 1.4 Million Gallons of Renewable Diesel in September
FinancialContent
·
19 minutes ago
Albertsons (NYSE:ACI) Reports Q3 CY2026 In Line With Expectations
MarketBeat
·
10 minutes ago
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Buy Rating at HC Wainwright
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA